Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sapporo Clinical Laboratory (TSE:9776) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sapporo Clinical Laboratory had a gross margin of 30.37% for the quarter that ended in Sep. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Sapporo Clinical Laboratory Gross Margin % Related Terms
Sapporo Clinical Laboratory Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sapporo Clinical Laboratory Gross Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, Sapporo Clinical Laboratory's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sapporo Clinical Laboratory Gross Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sapporo Clinical Laboratory's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Sapporo Clinical Laboratory's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sapporo Clinical Laboratory (TSE:9776) has a Gross Margin % of 30.37% as of Sep. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Sapporo Clinical Laboratory and its competitors. This is near median its historical median of 30.65. Over the past decade, Sapporo Clinical Laboratory's Gross Margin % has ranged from 29.84 to 33.08.
Is Sapporo Clinical Laboratory's Gross Margin % too high?
Sapporo Clinical Laboratory's current Gross Margin % of 30.37% is near median its 10-year median of 30.65. Over the past 10 years, this metric has ranged from a low of 29.84 to a high of 33.08. The Healthcare Providers & Services industry median Gross Margin % is 40.01. Sapporo Clinical Laboratory's value of 30.37% is 24.1% below this industry median. Overall, Sapporo Clinical Laboratory has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Sapporo Clinical Laboratory's Gross Margin % compare to competitors?
Sapporo Clinical Laboratory's Gross Margin % of 30.37% can be compared against companies in the Healthcare Providers & Services industry. The industry median Gross Margin % is 40.01. Sapporo Clinical Laboratory's value of 30.37% is 24.1% below this benchmark. Historically, Sapporo Clinical Laboratory's own Gross Margin % has ranged from 29.84 to 33.08 over the past decade. While the company's 10-year median is 30.65 vs. the industry median of 40.01, Sapporo Clinical Laboratory has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Healthcare Providers & Services company?
The median Gross Margin % among Healthcare Providers & Services companies is 40.01, based on 630 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sapporo Clinical Laboratory's current Gross Margin % of 30.37% is 24.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sapporo Clinical Laboratory and its competitors. For the Healthcare Providers & Services industry, the median Gross Margin % is 40.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sapporo Clinical Laboratory's current Gross Margin % is 30.37%, which is near median its own 10-year median of 30.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sapporo Clinical Laboratory stock overvalued right now?
Sapporo Clinical Laboratory (TSE:9776) has a current Gross Margin % of 30.37%. The stock's GF Value™ is 円1,041.47, compared to a current price of 円1,960.00 — trading 88.2% above its estimated fair value. The current Gross Margin % is 30.37%, which is near median its 10-year median of 30.65 and 24.1% below the Healthcare Providers & Services industry median of 40.01. Sapporo Clinical Laboratory's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sapporo Clinical Laboratory (TSE:9776), the current Gross Margin % is 30.37% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sapporo Clinical Laboratory (TSE:9776) Overvalued in 2026?
Based on GuruFocus' analysis, Sapporo Clinical Laboratory stock appears to be overvalued.
The current stock price of 円1,960.00 is trading 88.2% above its estimated GF Value™ of 円1,041.47.
Key valuation signals for TSE:9776:
Gross Margin %: 30.37% (near median its 10-year median of 30.65)
GF Value™: 円1,041.47 vs. price of 円1,960.00 (88.2% above fair value)
Industry Position: 24.1% below the Healthcare Providers & Services median
No single metric tells the full story. See the TSE:9776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sapporo Clinical Laboratory Inc. is a Japan based company engaged in offering clinical testing services. Its portfolio of services covers clinical examination, pathological examination, dispensing pharmacy, food hygiene environmental test, and radiation management. It is also engaged in the development of an integrated system for clinical testing.
43GF Score
Get the complete analysis for TSE:9776
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9776 has been successfully added to your 
